1. Home
  2. ACET vs BDSX Comparison

ACET vs BDSX Comparison

Compare ACET & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.54

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.79

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
BDSX
Founded
1947
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.5M
53.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ACET
BDSX
Price
$0.54
$7.79
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$8.50
$32.50
AVG Volume (30 Days)
1.9M
62.9K
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$80,173,000.00
Revenue This Year
N/A
$20.75
Revenue Next Year
N/A
$25.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.29
52 Week Low
$0.45
$3.44
52 Week High
$1.12
$32.20

Technical Indicators

Market Signals
Indicator
ACET
BDSX
Relative Strength Index (RSI) 33.71 51.69
Support Level $0.53 $7.68
Resistance Level $0.57 $8.17
Average True Range (ATR) 0.05 0.66
MACD 0.00 0.02
Stochastic Oscillator 5.35 55.68

Price Performance

Historical Comparison
ACET
BDSX

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Share on Social Networks: